For a growing number of travelers, vacation doesn't begin at the airport. It begins with leaving home in a state they'll be happy to return to.
SEATTLE, July 7, 2026 /PRNewswire/ -- Those final moments before a vacation are rarely spent relaxing.
Suitcases are waiting by the front door, chargers are plugged in, travel documents are double-checked, and somewhere between taking out the trash and watering the plants, many households find themselves doing one last walkthrough with a vacuum.
For many families, that final clean has become part of the vacation ritual. It's less about impressing anyone and more about giving their future selves one less thing to worry about when they return home.
A 2024 survey of 2,000 U.S. travelers found that 75% intentionally clean their homes before leaving on vacation, with laundry, dishes, bathroom cleaning, and vacuuming topping the list of last-minute chores. More than half (51%) say one of the biggest drawbacks of returning from a trip is walking into a home that still needs to be cleaned.
As this "vacation reset" becomes part of the travel routine, people are also looking for ways to make that final clean more efficient. With so many departure-day tasks competing for attention, convenience has become just as important as cleaning performance.
Products that reduce those extra steps can help simplify one of the busiest hours before a trip. Recently, the Tineco PURE ONE Station 5 PRO combines cordless cleaning with a self-emptying station that automatically collects dust and charges the vacuum between uses, helping homeowners complete one final whole-home clean without adding more maintenance to an already busy departure day.
Vacation may officially begin when the plane takes off or the car pulls out of the driveway, but for many households, it starts much earlier, with the peace of mind that comes from knowing they'll return to a home that's already been reset.
The Tineco PURE ONE Station 5 PRO is available through Tineco U.S. and select retail partners.
About Tineco
Tineco ("tin-co") was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 24 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation.
For more information, visit Tineco U.S.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
The Vacation Reset: More People Are Deep Cleaning Before They Leave Town
MUMBAI, India, July 7, 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.
During FY2026, Piramal Pharma reported revenue from operations of ₹8,869 crore, supported by a diversified business model with 17 global development and manufacturing facilities, commercial presence across more than 100 countries. Approximately 66% of the Company's revenue was generated from regulated markets, reinforcing its strong global footprint.
Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited, said, "FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth."
Key Highlights from the report:
- Piramal Pharma Solutions (CDMO), which contributed 55% of the Company's revenue, continued to strengthen its position as a leading integrated global CDMO, supporting over 500 global customers across the pharmaceutical and biotechnology ecosystem. During the year, the Company also continued strategic investments, including a commitment of US$90 million expansion in sterile injectables and payload linker capabilities
- Piramal Critical Care (CHG) further strengthened its leadership in US inhaled anesthesia market, retaining its No. 1 position in the US Sevoflurane market. Further, it completed the acquisition of Kenalog, while continuing to serve over 6,000 hospitals, surgical centres and clinics globally
- Piramal Consumer Healthcare delivered ₹1,274 crore in revenue and continued to strengthen its portfolio of over 25 consumer brands. The business launched 31 new products and SKUs during FY2026, while its Power Brands recorded 24% growth, contributing 52% of overall Consumer Healthcare revenue
- Quality remained a cornerstone of the Company's operations. During FY2026, Piramal Pharma successfully completed 38 regulatory inspections, including three USFDA inspections. We continue to maintain our status of zero Official Action Indicated (OAI) observations across all USFDA inspections, reinforcing the strength of PPL's quality systems and compliance standards
- The Company also continued to advance its sustainability agenda, achieving a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with the FY2022 baseline, following the approval of its science-based decarbonisation roadmap
- Piramal Pharma continued to strengthen its people first culture, with a global workforce of over 7,285 employees, while maintaining its strong commitment to workplace safety by achieving zero fatalities for the fifth consecutive year
For additional business highlights and key performance metrics, please refer to the accompanying FY2026 infographic.
For more information, please refer to the full report available at https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdf
About Piramal Pharma Limited
Piramal Pharma Limited (PPL, NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling wellness products across consumer healthcare categories. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments.
For more information, visit: Piramal Pharma | LinkedIn
* Includes one facility via PPL's minority investment in Yapan Bio.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones
